๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข GAAP EPS: $0.38 (Normalized Est. -$1.35, not directly comparable), vs. -$0.51 YoY.
โข Revenue: $1.313B (Est. $890.22M) โ , +29% YoY.
โข Net Income: $162M (vs. -$200M YoY).
โข U.S. Revenue: $780M.
โข International Revenue: $533M.
โข R&D Expenses: $583M, -27% YoY.
โข Cost of Sales: $318M, +54% YoY.
โข Cash & Investments: $8.0B.
โ
๐ฏ ๐๐ฎ๐ข๐๐๐ง๐๐
โข FY2026 Revenue Growth: +15%โ25%, raised from up to +10%.
โข FY2026 R&D Expenses: ~$2.7B, reduced from ~$2.9B.
โข FY2026 SG&A Expenses: ~$1.0B, unchanged.
โข FY2026 Capital Expenditures: ~$200M.
โข FY2026 Year-End Cash & Investments: $8.1Bโ$8.3B, raised from $4.7Bโ$5.2B.
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Q3 revenue beat consensus by ~47.5%, driven primarily by stronger international COVID vaccine sales.
โข Returned to GAAP profitability with $162M in net income, a $362M improvement YoY.
โข Phase 3 intismeran + KEYTRUDA reduced melanoma recurrence or death risk by 42% versus KEYTRUDA alone.
โข Distant metastasis or death risk declined 38% in the same Phase 3 trial.
โข Received U.S. approval for mFLUSIVA influenza vaccine, its fifth approved product globally.
โข Flu/COVID combination vaccine received approval in Canada following earlier EU authorization.
โข Norovirus Phase 3 interim analysis failed to meet early-success criteria; no additional cohort planned this season.
โข Reduced FY2026 R&D spending outlook by $200M amid continued cost discipline.
โข Completed ~$3B convertible notes financing, generating ~$2.6B in net proceeds.
โข Cash position increased to $8B, supported by debt financing despite a $950M litigation settlement payment and operating cash usage.
โข Pivotal propionic acidemia trial data expected in 2026.
โข Moderna Analyst Day scheduled for November 12.
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
โWe delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma.โ